Neuronetics, Inc.

As of November 6, 2018, Neuronetics, Inc. is considered risky and overvalued due to high Price to Book and EV to Sales ratios, negative returns on equity and capital employed, and a significantly lower P/E ratio compared to peers, indicating struggles in generating shareholder returns.

As of November 6, 2018, Neuronetics, Inc. is considered overvalued and categorized as risky due to significant negative financial metrics, including a Price to Book Value of 6.91 and a P/E ratio of -5.27, especially when compared to its peers.

As of May 1, 2025, the trend is mildly bullish due to daily moving averages and monthly KST, but caution is advised due to mixed signals from the weekly MACD and Bollinger Bands.

As of March 2022, the management team of Neuronetics, Inc. includes Mr. Brian Farley (Independent Non-Executive Chairman), Mr. Keith Sullivan (President and CEO), and Directors Mr. John Bakewell, Ms. Sheryl Conley, Dr. Wilfred Jaeger, and Mr. Glenn Muir. They are responsible for the company's strategic direction and operations.

Neuronetics, Inc. is a medical technology company that develops devices for treating psychiatric disorders, with a market cap of approximately $229.71 million. As of March 2025, it reported net sales of $32 million and a net loss of $13 million.

As of Jun 18, Neuronetics, Inc. has a market capitalization of 229.71 million and reported net sales of 89.45 million with a net profit of -48.02 million over the latest four quarters.